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(SNAP-25)Dopamine is believed to play an important role in the etiology of attention-deﬁcit/hyperactivity disorder
(ADHD). In our previous study, we showed that gene expression of dopamine D4 receptor decreased in the
spontaneously hypertensive rat (SHR) in the prefrontal cortex (PFC). In the present study, we explored the
potential causes of dysfunction in the dopamine system in ADHD. It is the ﬁrst time that neuronal activities in
both juvenile SHR and WKY rats have been measured by functional MRI (fMRI). Our results showed that in
PFC the Blood Oxygenation Level Dependent (BOLD) signal response in SHR was much higher than WKY
under stressful situations. We tested the effects of acute and repeated administration of amphetamine on
behavioral changes in SHR combined with the expression of the neuronal activity marker, c-fos, in the PFC.
Meanwhile dopamine-related gene expression was measured in the PFC after repeated administration of
amphetamine. We found that potential neuronal damage occurred through deﬁcit of D2-like receptor
protective functions in the PFC of the SHR. We also measured the expression of synaptosomal-associated
protein 25 (SNAP-25) in SHR in PFC. The results showed decreased expression of SNAP-25 mRNA in the PFC
of SHR; this defect disappeared after repeated injection of D-AMP.© 2009 Elsevier B.V. All rights reserved.1. IntroductionAttention-deﬁcit hyperactivity disorder (ADHD) in humans is
characterized by age-inappropriate inattention, impulsiveness, and
hyperactivity [1]. Dopamine is believed to play an important role in
the pathophysiology of ADHD. Genes involved in regulating the
dopamine system play a key role in the etiology of ADHD. In our
previous study, we showed that expression of dopamine D4 receptor
decreased in the spontaneously hypertensive rat (SHR) in the
prefrontal cortex (PFC) [2]. Several current studies have demonstrated
synaptosomal-associated protein 25 (SNAP-25) polymorphisms that
have been associated with ADHD [3,4]. SNAP-25 is involved in the
exocytosis of neurotransmitters from storage vesicles into synaptic
spaces [5]. Given these ﬁndings, it is possible that SNAP-25might have
a role in dopamine hypofunction in the prefrontal cortex in SHR, but to
date, this idea has not been assessed. Also, the relationship between
SNAP-25 and stimulant responses in ADHD is unclear. Therefore, it is
important to clarify the role of SNAP-25 in the regulation of the
dopamine system in ADHD and its relationship between stimulants852 2603 5031.
ll rights reserved.frequently used as treatments for ADHD, and to explore the causes of
dysfunction of the dopamine system in ADHD. Speciﬁcally, is the
dysfunction of the dopamine system a cause or result of the etiology of
ADHD?
With the improvements in imaging technology, more detailed
structural, functional and neurochemical proﬁles can be visualized
across the entire brain. Magnetic resonance imaging (MRI) morpho-
metric studies of ADHD have identiﬁed reductions in total brain
volume and in various regions of the brain (such as the prefrontal lobe,
caudate nucleus, corpus callosum and cerebellum) that are known to
be involved in the regulation of attention and impulsivity [6]. Also,
during functional magnetic resonance imaging (fMRI), ADHD children
have shown differences in frontostriatal activity, particularly in the
right prefrontal cortex and anterior cingulate [7–9]. Other relevant
neuroimaging studies have shown dysfunction of the dopaminergic
system in ADHD children [10]. Animal models can help to elucidate
and further the understanding of ADHD. Juvenile spontaneously
hypertensive rats (SHR) (before hypertension develops) show many
behavioral characteristics similar to ADHD [11,12]. SHR, therefore,
are the most frequently used model of ADHD [12], however there is
no evidence as yet of neuron activities in the PFC in juvenile SHR
using fMRI.
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amphetamine, and pemoline) are the most common treatments for
ADHD [13], even though the precise etiology and pathological
mechanisms underlying ADHD are poorly understood. The mecha-
nism of action of D-amphetamine (D-AMP or AMPH) is to release
dopamine from presynaptic nerve terminals in addition to inhibiting
reuptake of dopamine [14]. However, there has been no evidence to
show the effects of repeated administration of amphetamine or the
effects of systemic administration of amphetamine on expression of
dopamine-related genes. In the present study, we measured these
effects in the juvenile spontaneously hypertensive rat, the most
frequently used model of ADHD [12], to examine any neurobiological
alterations.
As the prefrontal cortex is the major affected brain area in ADHD
[15], we focused our study on the biochemical alterations of the
prefrontal cortex in SHR after administration of psychostimulant
drugs. We tested the effects of acute and repeated administration of
amphetamine on behavioral changes in SHR combined with the
expression of the neuronal activity marker, c-fos, in the PFC after an
acute administration of amphetamine. This is the ﬁrst time the
neuronal activities in the PFC of SHR have been demonstrated under
fMRI. Also, the expression of dopamine-related genes was measured
in the PFC after repeated administration of amphetamine. Further-
more, we measured the expression of SNAP-25 in SHR in PFC and
expression of SNAP-25 with repeated amphetamine treatment.
2. Materials and methods
2.1. Animals
Juvenile male spontaneously hypertensive rats (SHR) aged 4–
6 weeks old and age- and gender-matched genetic control Wistar–
Kyoto rats (WKY) were obtained from the Laboratory Animal Services
Centre, The Chinese University of Hong Kong (CUHK). The rats had
free access to standard laboratory rodent chow and water, and were
housed in a room with 12 h light–dark cycle. Temperature and
humidity were maintained at 22±1 °C and 45–55%, respectively. The
experiments were approved by the Animal Experimentation Ethics
Committee, CUHK.
2.2. Behavioral testing
2.2.1. Experiment 1: effects of an acute systemic administration of D-AMP
on locomotor activity
Four-week-old SHR and WKY (n=5/group/strain) were main-
tained in the Laboratory Animal Services Centre, the Chinese
University of Hong Kong (CUHK). Rats of the same strain were housed
ﬁve per cage and after at least 3 days of acclimation, were divided into
the following ﬁve treatment groups for: (1) D-AMP (gift from the
Department of Pharmacology, CUHK) diluted with 0.9% saline to
0.1 mg/kg intraperitoneal (IP) injection; (2) D-AMP 0.3 mg/kg IP; (3)
D-AMP 1 mg/kg IP; (4) D-AMP 3 mg/kg IP; and (5) D-AMP 10 mg/kg
IP injection. The saline administration rats were the control group. The
drugs and saline were administrated in the home cages once between
4 pm and 6 pm, and all the rats were pretreated with saline by
intraperitoneal injection for 2 days before the drug and saline
administration in order to adapt them to the stress of injection.
The apparatus and methods were the same as mentioned in our
previous study [2]. The open-ﬁeld (OF) box was a 50-cm3 cube
constructed from black Plexiglas. Animals were placed into the box
and were videotaped for 5 min using an Animal Behavior Recognition
System (Institute of Psychology, Chinese Academy of Sciences,
Beijing, China). We recorded locomotion activities for 5 min in SHR
and WKY after 15-min injection of D-AMP. We measured locomotor
activities on rats after 0 min, 15 min and 30 min injection of D-AMP
(data not shown).2.2.2. Experiment 2: effects of the repeated administration of D-AMP on
locomotor activity
The strains of rats, 4-week-old SHR and WKY (n=5/group/
strain), were each divided into two groups respectively: 1) D-AMP
3mg/kg IP for 7 days; 2) 0.9% saline 1ml/kg IP for 7 days. All rats were
pretreated with saline by intraperitoneal injection for 2 days before
drug administration to reduce the stress from injection. The drugs
were administered in the home cages each day between 4 pm and
6 pm to coincide with the recording of locomotion activities.
2.2.3. Experiment 3: effects of an acute systemic administration of
D-AMP on prepulse inhibition (PPI)
Four-week-old SHR and WKY (n=5/group/strain) were housed
ﬁve per cage. After at least 3 days of acclimation, each strainwasdivided
into four groups: (1) 0.9% saline 1ml/kg IP; (2) D-AMP 1mg/kg IP; (3)
D-AMP 3 mg/kg IP; and (4) D-AMP 5 mg/kg IP injection.
The drugs were administered in the home cages once between
4 pm and 6 pm, and the rats were pretreated with saline by
intraperitoneal injection for 2 days before the drug administration.
The apparatus and methods were the same as described in our
previous studies [2]. Prepulse inhibition was measured in one startle
chamber (San Diego Instruments, San Diego, CA). Startle responses
were measured by an accelerometer in response to acoustic stimuli
delivered by a white noise generator (4–19 kHz; SR-Lab, San Diego,
CA). A test session consisted of placing the animals in the startle
chamber under 70 dB background noise for a 5 min acclimatization
period after which they were exposed to a total of 37 trials separated
by variable inter-stimulus intervals that averaged 15 s [16,17]. The
intensity of the prepulse stimulus varied from 3 to15 dB above the
background noise level of 3 dB increments. These trials were
presented randomly, with the restriction that no more than two trials
of the same type could be run in succession. For data analysis, the
average of the last 10 startle trials was taken as the measure of startle
reactivity for each animal. We also averaged the 5 trials taken at each
of the 5 prepulse intensities, and then expressed these values as a
percentage of the average reactivity for the 10 startle trials, using the
formula: [(startle−prepulse)/startle]×100. We started prepulse
inhibition tasks 15 min after they were treated with D-AMP.
2.3. Functional magnetic resonance imaging (fMRI)
There were 5 rats in each of the SHR and WKY groups. They were
anesthetized with amixture of ketamine (100mg/kg, IP) and xylazine
(10 mg/kg, IP) and placed into a head and body restrainer.
Experiments were performed on a 1.5 T clinical MR scanner (Intera
NT, Philips Medical Systems, Best, the Netherlands) a microscopy
radiofrequency coil (M-23, Philips) of 2.3 cm diameter was used for
signal reception. The coil was carefully placed over the head of each
animal and a standardized imaging protocol was applied. For
structural imaging, a turbo spin echo T2-weighted sequence [repeti-
tion time (TR), 446 ms; echo time (TE) 100 ms; imaging matrix,
256×256; ﬁeld of view (FOV), 60 mm] was employed and this scan
was performed for each animal before functional scanning. Functional
imaging of the animal brains was performed using a single shot,
gradient-echo, echo planar imaging (EPI) sequence with the following
parameters: FOV, 60 mm; slice thickness, 0.8 mm; TR, 2000 ms; TE,
33 ms; ﬂip angle 90°; matrix, 64×64. Sixty-four dynamic scans were
acquired using the latter imaging sequence in the transverse planewith
a scanning time of 2 min and 16 s. Each run consisted of dummy scan
(dynamic 1–4), “off” scan (dynamic 5–19), “on” scan (dynamic 20–34),
“off” scan (dynamic 35–49) and lastly “on” scan (dynamic 50–64). First,
we put the rat's tail between two plates, then put a 500 g weight onto
the plate (the area of the plate is about 14×12 cm). The area of a rat's
tail is approximately 5 cm2 and the gravity of a 500 g mass is 4.9 N.
Therefore, 100 g/cm2 weight was given during the “on” scan interval
and the weight was taken off during the “off” scan interval.
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activation processing tool (View Forum release 4.2, Phillips Medical
Systems, Best, The Netherlands). For each voxel in a given slice, t-tests
between the “on” and “off” periods, including a Bonferroni correction
for the total number of voxels in a slice, were performed and Z-scores
were computed. Clusters of activated voxels were determined using a
Z-score threshold of 1.6 and a minimum cluster size of 10. Activated
regions of interest were matched with the anatomical T2-weighted
images of identical slice thickness and location. The Z-scores of
clusters contained in the transverse T2-weighted slices showing the
prefrontal cortex brain zone were calculated.
2.4. Determination of dopamine concentration by using an
enzyme-linked immunosorbent assay (ELISA) in mesocortical and
mesolimbic dopamine system between SHR and WKY
Rats (n=6 per group) were killed by decapitation and the brains
were removed and dissected. Total protein samples were prepared
from the midbrain, prefrontal cortex, nucleus accumbens and
amygdala, and were immediately immersed in liquid nitrogen.
Afterwards, the specimens were stored at −80 °C until future use.
Brain tissue samples (50mgwetweight)were homogenized in 0.1N
HCl and 1 mM EDTA. The homogenate was centrifuged at 15,000 g for
15 min at 4 °C and the supernatant obtained was used freshly or stored
at−80 °C. Dopamine concentration was evaluated by using dopamine
ELISA kit (IBL, RE59 161, Hamburg, Germany). The optimal standard
curve with dopamine at known concentrations (0, 12, 35, 115, 450,
2250 ng/ml) was obtained by using a cubic spline curve-ﬁlling
technique [18]. Optical density was recorded for the standard samples,
controls, and experimental samples. The concentration was calculated
according to the cubic formulae.
2.5. c-fos protein expression in the prefrontal cortex after an acute
systemic administration of D-AMP
The method and dosage of D-AMP usage were the same as
mentioned above in 2.2.1. Experiment 1.
SHR and WKY rats (n=5/group/strain) were killed 24 h after the
last drug injection. In order to analyze the protein expression of c-fos,
Western blot was used with enhanced chemical luminescence (ECL).
100 mg brain tissue samples was homogenized in 0.5 ml of 50 mM
Tris–HCl (pH 7.4) containing 150 mM NaCl, 5 mM EDTA, 0.1% sodium
dodecyl sulphate (SDS), 1% Triton X-100, 0.1 mg/ml PMSF, 1 μg/ml
leupeptin, 1 μg/ml pepstain A, and 5 jig/ml aprotinin. The homo-
genate was centrifuged at 14,000 rpm for 3 min at 4 °C and the
supernatant obtained was either used immediately or stored at
−80 °C until use. The protein concentration of the extract was
determined by DC protein assay (DC protein assay kit, Bio-Rad, CA). All
the samples were equalized to 70 jig from the prefrontal cortex of SHR
and WKY. Tissue homogenates were mixed with 2×loading buffer
(100 mM Tris–HCl of pH 6.8, 4% sodium dodecyl sulphate, 200 nM
dithiothreitol, 0.2% bromophenol blue, and 20% glycerol). The mixture
was then boiled for 6 min before being loaded onto a 12% SDS-
polyacrylamide gel. Electrophoresis was performed at 60 V for
120 min followed by semi-dry transfer onto nitrocellulose membrane
at 10 V for 1 h. The membrane was then blocked for 1 h in blocking
solution containing 5% non-fat dry milk, 0.05% Tween-20, and
phosphate buffered saline. The blocked membrane was incubated
overnight with rabbit polyclonal c-fos (1:1000) (Santa Cruz Biotech-
nology, INC, SC-253). After 30 min washing with 0.05% Tween-20 and
phosphate buffered saline, the membrane was incubated with the
appropriate horseradish peroxidase (HRP) conjugated secondary
antibody for 1 h (1:3000 for anti-rabbit IgG-HRP, sc-2077). Bound
antibody was detected by the ECL-plus kit from Amersham. The
optical density of the immunoreactive bands was detected with a
MultiImage™ II light cabinet (DE-500) that was equipped withFlurochem Beta 1.1 software (Alpha Innotech Corp., CA, USA). Band
density values were normalized to β-Actin. Equal loading samples
were normalized to β-Actin. Mean band densities were normalized to
the corresponding values for the control samples of WKY.
2.6. Expression of c-fos and dopamine-related genes in the prefrontal
cortex after repeated use of D-AMP
SHR and WKY (n=5/group/strain) were divided into two groups
for each strain: 1) D-AMP 3 mg/kg i.p. for 7 days; and 2) 0.9% saline
1 ml/kg i.p. for 7 days. The drugs and saline were administered in the
home cages each day between 4 pm and 6 pm, and all the rats were
pretreated with saline by intraperitoneal injection for 2 days before
the drug and saline administrations.
Rats were killed by decapitation 24 h after the last drug injection
and the brains were removed immediately. Total RNA samples were
prepared from the prefrontal cortex. It was important that the total
RNAwas free from genomic DNA contamination. The A260/A280 ratio
was at least 1.8 and the agarose gel showed that 28S band was more
intense than 18S ribosomal RNA. TRIZOL reagent (Invitrogen™, USA)
was used for RNA extraction. cDNA was synthesized from 5 μg of total
RNA in a 40 μl reaction containing Oligo(dT) 15 and Moloney murine
leukaemia virus (MMLV) reverse transcriptase (Invitrogen™, USA).
Real-time quantitative PCR was performed using a 7700 Sequence
Detection System (Applied Biosystems, Foster City, CA, USA). SYBR
Green chemistry was used to perform real-time PCR analysis [19–21],
which provided the simplest and most economical format for
detecting and quantifying PCR products in real-time reactions. Each
25 μl reactionmixture contained SYBRGreen PCRMasterMix (Applied
Biosystems, Foster City, CA, USA), the primers (300mmol/l for β-Actin
and 900mmol/l for c-fos, dopamine D1-5 receptors, DAT and TH), and
0.5μl cDNA sample. Ampliﬁcationwas performed in 96-well plates and
the PCR cycle consisted of 1 cycle at 95 °C or 10 min, and 40 cycles at
95 °C for 15 s and 60 °C for 1 min. All primers were designed and
checked with the Blat (http://genome.ucsc.edu/index.html?org=
Human&db=hg1 8&hgsid=80649300) so that no non-speciﬁc pro-
duct would be ampliﬁed. Speciﬁcity was also veriﬁed by electro-
phoresis of the PCR products that showed only one band for each PCR
on the gel, and by one single peak in the melting curve analysis in the
real-time PCR reaction (data not shown). Each samplewas analyzed in
triplicate. β-Actin was used to normalize results of the targeted genes
[22]. Changes in gene expression between SHR and WKY brain
samples were calculated from the differences in threshold cycles (CT
values). The ΔΔCT method was used to determine the relative gene
quantity (Fold induction=2− [ΔΔ]). However, before using this
method, the efﬁciencies of target and reference genes were demon-
strated to be approximately equal [23,24].
2.7. SNAP-25 gene expression in the PFC
2.7.1. Basal SNAP-25 gene expression in the PFC between SHR and WKY
SHR and WKY (n=5/group/strain) were killed and processed
using real-time PCR as described above (see 2.5). SYBR Green
chemistry was used to perform real-time PCR analysis [18–21],
which provided the simplest and most economical format for
detecting and quantifying PCR products in real-time reactions. Each
25 μl reactionmixture contained SYBRGreen PCRMasterMix (Applied
Biosystems, Foster City, CA, USA), the primers (300mmol/l for β-Actin
and 900 mmol/l for SNAP-25), and 0.5 μl cDNA sample. Ampliﬁcation
was performed in 96-well plates and the PCR cycle consisted of 1 cycle
at 95 °C or 10 min, 40 cycles at 95 °C for 15 s and 60 °C for 1 min.
2.7.2. SNAP-25 gene expression in the PFC after the repeated use of D-AMP
SHR and WKY (n=5/group/strain) were divided into two groups
for each strain: 1) D-AMP 3 mg/kg i.p. for 7 days; and 2) 0.9% saline
1 ml/kg i.p. for 7 days. The drugs were administered in the home
Fig. 2. Locomotor activity was measured after repeated injection 15 min of D-AMP and
saline. Four groups of rats were treated with saline and 3 mg/kg D-AMP for 7 days. The
total distance during a 5 min period in an open-ﬁeld box was measured after drug
injection. During the 7 days of injection of amphetamine, both SHR and WKY showed
signiﬁcantly greater increase in locomotor activity (ANOVA multi-variate, F=8.716,
pb0.0001), but there was no difference after saline treatment in 7 days in SHR and
WKY. SHR showed much more locomotor activity thanWKYafter saline administration
(ANOVAmulti-variate, F=66.52, pb0.0001). Post Hoc Tests (Dunnett, 2-sided) showed
signiﬁcant differences between day 1, day 2 and day 7 after administration of AMPH.
⁎⁎pb0.0001 represented the signiﬁcant differences in SHR or WKY after amphetamine
injection, when compared to saline injection in SHR or WKY. ##pb0.0001 represented
the signiﬁcant differences between SHR and WKY after saline injection.
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with saline by intraperitoneal injection for 2 days before the drug
administration.
Animals were killed 24 h after the last drug injection and real-time
PCRwas used tomeasure the expression of dopamine-related genes in
the PFC. RT-PCR method was the same as described above in 2.7.1.
2.8. Statistical analysis
Where appropriate, data analysis was followed by the independent
sample t-test, one-way ANOVA, and general linear model ANOVA
(SPSS version 13.0 and Sigmaplot version 9.0). When signiﬁcant
difference (pb0.05) was found, a multiple comparison Post Hoc Test
(Bonferroni) was applied to identify groups differing signiﬁcantly
from each other. Data were reported as mean±SEM unless otherwise
stated.
3. Results
3.1. Behavioral testing
3.1.1. Experiment 1: effects of an acute systemic administration of D-AMP
on locomotor activity
The 2×6 (groups×different treatments with saline and 5 different
dosages of D-AMP) ANOVA univariate analysis showed a signiﬁcant
difference in the different treatments (F=24.043, pb0.0001). Also
the interaction between groups and different treatments showed
signiﬁcant difference (F=4.06, pb0.005). Post-hoc Bonferroni tests
revealed that these differences mainly came from the saline compared
to all the different dosages of D-AMP. Both of SHR and WKY showed
signiﬁcant decreased locomotor activities after an acute systemic
amphetamine treatment (see Fig. 1).
3.1.2. Experiment 2: effects of the repeated administration of D-AMP on
locomotor activity
Increased locomotor activity was due to administration of amphe-
taminewhich is independent of rat strain but dependent on the time of
treatment. 2×4×7 (strains× treatment×days) ANOVA analysis
showed the differences between strains only in saline treatment
group (F=66.52, pb0.0001). Post Hoc Tests (Bonferroni) showedFig. 1. Locomotor activitywasmeasured after acute injection 15min of different dosages
of D-AMP. Rats were treated with saline or different dosages of amphetamine. The total
distance for a 5 min period in an open-ﬁeld boxwas measured after drug injection. 2×6
(groups×different treatment) ANOVA univariate analysis showed the signiﬁcant
difference in different treatments (F=24.043, pb0.0001). Post hoc comparisons by
Bonferroni, the differences in locomotion under the saline and systematic amphetamine
administration mainly came from that of saline compared to all the different dosages of
D-AMP. ⁎⁎pb0.0001 represented the signiﬁcant differences in saline when compared
with different dosages of D-AMP treatment both in SHR and WKY.signiﬁcant differences in day 1, day 2 and day 7 after administration of
D-AMP (pb0.05). Our data showed that amphetamine can induce
hyper-locomotor activity in both SHR and WKY (F=8.716, pb0.0001)
and eliminate the differences of locomotor activities before ampheta-
mine administration between SHR and WKY (see Fig. 2).
3.1.3. Experiment 3: effects of an acute systemic administration of D-AMP
on prepulse inhibition (PPI)
It was obvious that with the increase of pre-pulse intensities, the
inhibition ability increased. But after AMPH administration, this trend
became variable except for the behavioral changes after 3 mg/kg
AMPH administration in WKY and 3 mg/kg, 5 mg/kg in SHR (see
Fig. 3). The 2×4×5 (strains×treatments×prepulse intensities)
ANOVA multi-variate analysis showed a main effect on interaction
between different pre-pulse intensities and different treatments
(F=2.477, pb0.01). Also we found the main effects came from
interaction between different pre-pulse intensities and different rat
strains (F=4.41, pb0.01). There was a signiﬁcant difference of
inhibition ability between SHR and WKY (F=7.31, pb0.05). After
saline administration, SHR showed inhibition deﬁcit in 79, 82, and
85 dB pre-pulse intensities when compared with WKY, but on the
other hand better inhibition ability in lower pre-pulse intensities— 73
and 76 dB. There was a signiﬁcant difference between the saline and
different AMPH dosages for inhibition ability (F=2.89, p≤0.05). After
AMPH administration, inhibition ability showed a deﬁcit in both WKY
and SHR in the different pre-pulse intensities except for 73 dB inWKY
which had better PPI ability. We also found that SHR had a similar
inhibitory ability to WKY after administration of 3 mg/kg ampheta-
mine (see Fig. 3).
3.2. Functional magnetic resonance imaging (fMRI)
The functional MRI imaging showed positive BOLD signals (red) in
the cortex, striatum, cerebellum, hippocampus, caudate putamen
(CPu), thalamus, hypothalamus, midbrain, and frontal cortex of SHR
when a 500-g weight was put onto a rat's tail (see Fig. 4B). InWKY, the
fMRI showed high activity of positive BOLD signals (red) in the cortex,
cerebellum, CPu, thalamus and the frontal cortex during pain
Fig. 3. Prepulse inhibition (PPI) after an acute systemic amphetamine (D-AMP) treatment. There were four types of treatment: saline, 1 mg/kg D-AMP, 3 mg/kg D-AMP and 5 mg/kg
D-AMP. The intensity of the prepulse stimulus varied from 3–15 dB above the background noise level (70 dB) of 3 dB increments. % inhibition was measured under the 73 dB (PP3),
76 dB (PP6), 79 dB (PP9), 82 dB (PP12) and 85 dB (PP15) prepulse stimulants. There was a signiﬁcant difference of inhibition ability between SHR and WKY (ANOVA, F=7.31,
pb0.05). Meanwhile, there was a signiﬁcant difference between the saline and different AMPH dosages in inhibition ability (F=2.89, p≤0.05). The interaction between different
pre-pulse intensities and different treatments had a statistic signiﬁcance within-subjects (F=2.477, pb0.01). Also the interaction between different pre-pulse intensities and
different rats' strains showed a statistic signiﬁcance (F=4.41, pb0.01). ⁎pb0.05 represented the signiﬁcant differences between SHR and WKY after saline treatment.
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areas was according to Pellegrino's ‘A stereotaxic atlas of the rat brain’
and DiFranze's work [25] (see Fig. 4A).
Compared to WKY, SHR showed multiple-system activation under
this stressful stimulus, not only in the sensory-discriminative brain
areas but in the limbic system as well. The number of positive BOLD
voxels measured in PFC in SHR was 23.60±5.22 and in WKY was
8.66±2.85 (pb0.05). In addition, there was a signiﬁcant difference
between SHR and WKY after normalization of data (SHR 0.00097±
0.00022, WKY 0.00032±0.000095, pb0.05) (see Fig. 5).
3.3. Determination of dopamine concentration by using an
enzyme-linked immunosorbent assay (ELISA) in mesocortical and
mesolimbic dopamine system between SHR and WKY
The cubic formulae was y=−0.729+10.817x−13.688x2+
6.435x3. This cubic curve provided a good ﬁt of the data obtained
from the positive control and standard.
There were signiﬁcantly lower dopamine concentrations (ng/ml)
in prefrontal cortex, midbrain and amygdala in SHR compared toWKY
(dopamine concentration in the prefrontal cortex: WKY: 146.40±
13.71, SHR: 104.33±4.81, pb0.05; in the midbrain: WKY: 138.20±
18.27, SHR: 88.00±9.98, pb0.05; in the amygdala: WKY: 25.00±
2.04, SHR: 13.25±1.65, pb0.01) (see Fig. 6). There was no signiﬁcant
difference in nucleus accumbens (NAc) between SHR and WKY using
an independent sample t-test.
3.4. c-fos protein expression in the prefrontal cortex after the systemic
D-AMP administration
In prefrontal cortex (PFC), there was a signiﬁcant difference in c-fos
protein synthesis between SHR and WKY after injection of 3 mg/kg
amphetamine. SHR showed a signiﬁcantly higher level of expression of
c-fos in PFC than WKY (SHR 3.27±0.28, WKY 2.25±0.15, pb0.05)
(see Fig. 7). There were no differences in c-fos synthesis with other
amphetamine dosages using independent sample t-test.3.5. Expression of c-fos and dopamine-related genes in the prefrontal
cortex after repeated use of D-AMP
SHR showed signiﬁcant upregulation of c-fos by a factor of 9.264
compared to WKY after amphetamine injection (pb0.05). Measure-
ments of dopa decarboxylase (DDC) and dopamine beta-hydroxylase
(DBH), enzymes involved in dopamine synthesis, did not show any
differences. Also there were no signiﬁcant differences in dopamine-
related gene expression (including dopamine D1–5 receptors and the
two key enzymes for dopamine synthesis and transportation, respec-
tively TH andDAT) between SHR andWKY in the PFC after repeated use
of amphetamine (see Fig. 8A).However, therewere signiﬁcant increases
in dopamine 1, 2 and 3 receptors in WKY treated with amphetamine
compared to treatmentwith saline. The relative gene expression (saline
compared to AMPH in WKY) of dopamine 1 receptor (D1R) was 3.151,
while β-Actin was 0.706. D1R was upregulated 4.47 times in WKY
treated with amphetamine (pb0.05). The relative expression of
dopamine 2 receptor (D2R) was 3.492, β-Actin was 0.706. Therefore,
the D2R was upregulated by a factor of 4.95 in WKY treated with
amphetamine (pb0.01). The relative expressionof dopamine 3 receptor
(D3R)was4.093,β-Actinwas0.706. Therefore, thedopamine3 receptor
was upregulated by a factor of 5.8 in WKY treated with amphetamine
(pb0.05) (see Fig. 8B). In SHR, there was a signiﬁcant increase in
dopamine 1 receptor after treatment with amphetamine compared to
treatment with saline. The relative expression of dopamine 1 receptor
(D1R) was 1.763, β-Actin was 0.869. The dopamine 1 receptor was
upregulated by a factor of 2.03 (pb0.05) (see Fig. 8B).
3.6. SNAP-25 gene expression in the PFC between SHR and WKY
3.6.1. Basal SNAP-25 gene expression in the PFC between SHR and WKY
There was a signiﬁcant difference in SNAP-25 gene expression in
PFC between SHR and WKY. In the PFC, the normalized relative
expression of SNAP-25 was 0.683, β-Actin was 0.745 (SHR compared
to WKY). Therefore, SNAP-25 gene expression was downregulated in
SHR compared to WKY by a factor of 1.414 (pb0.05) (see Fig. 9).
Fig. 4. (A) Anatomical images (MRI) showing 10 regions of interest. These brain areaswere targeted according to Pellegrino's ‘A stereotaxic atlas of the rat brain’ [55]. I PFC (prefrontal
cortex), II Hippocampus, III SC (superior colliculus) and IC (inferior colliculus), IV Cerebellum, V Thalamus, VI CPu (caudate putamen), VIIMidbrain, VIII Hypothalamus, IX Pons, X
Cortex. (B) SHR showing Blood Oxygenation Level Dependent (BOLD) activation in many brain structures in response to a 500-g weight onto a rat's tail. The positive BOLD signals
were present in the cortex, cerebellum, hippocampus, CPu, thalamus, hypothalamus, midbrain, and prefrontal cortex (PFC). (C) Region-speciﬁc activation maps of WKY induced by a
500-g weight onto a rat's tail. Positive BOLD signals are shown in the cortex, cerebellum, CPu, thalamus, hypothalamus, and prefrontal cortex. (D) Signal intensity changes from the
prefrontal cortex during stimulation period.
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Fig. 5. The volume of positive Blood Oxygenation Level Dependent (BOLD) signal in the
prefrontal cortex was normalized by thewhole brain volume. Signiﬁcant differences are
indicated by ⁎pb0.05 between SHR and WKY.
Fig. 6. Differences of dopamine concentration in the prefrontal cortex (PFC), midbrain,
nucleus accumbens (NAc) and amygdala. This is the baseline expression of dopamine
concentration measured by using ELISA in the different brain areas between SHR and
WKY. There were signiﬁcantly lower dopamine concentrations (ng/ml) in prefrontal
cortex, midbrain and amygdala in SHR compared toWKY. All the data we obtained were
from the cubic formulae (y=−0.729+10.817x−13.688x2+6.435x3). This cubic curve
model provided a good ﬁt of the data obtained from the positive control and standard.
Signiﬁcant differences of dopamine concentration between SHR andWKYare indicated
by ⁎pb0.05, ⁎⁎pb0.01.
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administration of D-AMP
Although SHR showed lower SNAP-25 expression in PFC when
compared to WKY, there were no signiﬁcant differences in SNAP-25
gene expression in PFC between SHR and WKY after D-AMP
administration for 7 days (SNAP-25 gene expression was down-
regulated in SHR compared to WKY by a factor of 1.309, p=0.65).
Further, there were no signiﬁcant differences in SNAP-25 expression
in the PFC in SHR with amphetamine administration when compared
to saline-treated SHR. The normalized relative expression of SNAP-25
was 1.560, β-Actinwas 1.11 (SHR saline treatment compared to AMPH
treatment) (SNAP-25 upregulated by factor 1.405, p=0.189). Similar
results were found in WKY. The normalized relative expression of
SNAP-25 was 1.105, while β-Actin was 0.922. Therefore, SNAP-25 was
upregulated by a factor of 1.2, p=0.053.
4. Discussion
In this study, dopamine concentrationwas found to be signiﬁcantly
lower in the prefrontal cortex, midbrain, and amygdala in the SHR.
This would suggest that dopamine storage or release is hypofunctional
in mesocortical and mesolimbic dopamine pathways in the SHR.
Attention deﬁcit and poor behavioral planning may result from
decreased dopaminergic activity in the mesocortical dopamine path-
way [26]. Also less dopamine concentration was found in the
amygdala of SHR. A recent fMRI study found that amygdala showed
slower response latencies when approaching negative emotional
content [27]. This represents dysfunction in the amygdala, which
might be correlated with less dopamine release or storage in
amygdala. However, the cause–effect relationship should be demon-
strated through further studies. We did not ﬁnd any differences in
dopamine concentration in nucleus accumbens (NAc) between SHR
and WKY in this experiment. Carboni et al. [28] reported that the
extracellular dopamine concentration in the NAc shell was higher in
SHR. A possible reason is that it was difﬁcult to precisely dissect NAc
into shell and core in vitro, so it was difﬁcult to determine the
differences in the whole NAc.
One competing hypothesis about the etiology of ADHD is the
“frontal lobe hypothesis”, which suggests that ADHD is caused by
problems of inhibitionmediated by genetically-based abnormalities in
those frontal structures of the brain responsible for executive
functions [29,30]. Our studies suggest that lower levels of dopamine
concentration and lower dopamine D4 receptor gene expression in the
frontal cortex may translate into a relatively lower inhibitory
dopaminergic inﬂuence, leading to hyperactivity in SHR. Theprefrontal cortex was the major affected brain area in SHR, hence, in
our studies we focused on the prefrontal cortex alterations in SHR.
When neural activity increases in a region of the brain, the local
MR signal produced in that part of the brain increases by a small
amount due to changes in blood oxygenation. Functional MRI based
on the BOLD effect is now a widely used tool for probing the working
brain. The goal of fMRI studies is to map patterns of local changes in
the MR signal in the brain as an indicator of neural activity associated
with particular stimuli. Using fMRI, we tried to discoverwhether there
were any differences in neuronal activity under stressful stimulation.
A 500-g weight was put onto the rat's tail as an acute stressful
stimulus, which might include pain and pressure stimuli. We found
that both rat strains had similar bilateral activated brain areas,
including striatum, caudate, putamen, thalamus, cerebellum, and
frontal cortex. These cortical and subcortical areas were consistent
with those activated by other acute and chronic pain stimuli [31,32].
As we compared the positive signals of BOLD in the prefrontal cortex,
SHR showed a signiﬁcantly larger volume of activated prefrontal
cortex than WKY, indicating that there might be more neuronal
activities or increased glucose metabolism in PFC of SHR in the
stressful environment. The PFC of SHR might be hyper-responsive to
stressful stimulation, just as SHR are hyper-adrenergic to stress stimuli
with consequently higher levels of plasma corticosterone [33]. Normal
brain development requires the coordinated maturation of many
processes occurring in a temporally and regionally dependentmanner.
Stress is the most important stimulus to demonstrate coordinated
maturation of the brain's anatomical parts (volume loss of different
brain areas, such as hippocampus and PFC) from its functional parts
(hypothalamo–pituitary–adrenal or HPA function) [34,35]. Stress
exposure, just like amphetamine administration, can induce excessive
catecholamine release [36]. Therefore, stress could trigger the
potential dysfunction in the brain. In this study, SHR showed a
dysfunctional stress axis similar to reports on ADHD children [37]. A
more important ﬁnding in our research was dysfunction in PFC, which
is one of the most sensitive brain areas to stress exposure [36]. We
believe this is the ﬁrst demonstration of PFC dysfunction in SHR using
in vivo imaging.
In order to identify the potential causes of dysfunction in PFC of
SHR, we studied the effects of D-AMP on behavioral and neurobio-
logical changes. The results of this part of the experiment are
Fig. 7. (A) Western blotting plot of c-fos protein and β-Actin in the prefrontal cortex of SHR and WKY after an acute systemic amphetamine treatment. SHR and WKY rats (n=5/
group/strain) were killed 24 h after the last drug injection. Then wemeasured c-fos protein expression using Western blotting. The left side showed c-fos protein and β-Actin in the
prefrontal cortex of SHR. The right side showed those ofWKY. The upper plot showed c-fos protein and the lower plot showed β-Actin. (B) Relative density of c-fos protein expression
in the prefrontal cortex after the systemic amphetamine treatment. ⁎pb0.05, WKY vs. SHR. (A) Different dopamine-related gene expression proﬁles normalized with β-Actin when
WKY received amphetamine compared to SHR received amphetamine. (B) Different dopamine-related gene expression proﬁles normalizedwith β-Actin. (Left columns showedWKY
with saline administration compared to WKY received amphetamine. Right columns showed SHR with saline administration compared to SHR received amphetamine).
773Q. Li et al. / Biochimica et Biophysica Acta 1792 (2009) 766–776summarized as follows: (1) An acute D-AMP treatment could decrease
the locomotor activities in SHR receiving the systemic dosage of D-
AMP. The differences in locomotor activity after systemic administra-
tion of D-AMP between SHR and WKY disappeared. (2) The defect of
inhibition ability in SHR under 85-dB prepulse stimulus disappeared
after administration of 1 mg/kg and 3 mg/kg amphetamine. (3) The
repeated 3 mg/kg D-AMP treatment starting from the second day
increased the locomotor activities in both SHR and WKY. (4) SHR
exhibited increased c-fos synthesis after 3 mg/kg D-AMP treatment in
the prefrontal cortex. (5) There was no difference in expression of
dopamine-related gene between SHR and WKY after repeated
treatment of 3 mg/kg D-AMP, although D1R, D2R and D3R gene
expression increased in WKY, and D1R gene expression was increased
in SHR after D-AMP treatment.
Clinical research has revealed that the responses of normal and
ADHD children to psychostimulants are qualitatively similar and
include reductions in activity level and impulsivity, as well as
enhancement of attention-related processes [38]. In this experiment,
both SHR and WKY rats exhibited reductions in locomotor activities
after a single exposure to D-AMP at the lower dosage level. At the
moderately low dose (1 and 3 mg/kg), SHR manifested hypoactivities
compared to the saline-injected group. Following the higher dose
(10 mg/kg) of D-AMP, intensive stereotypical behavior could be
observed in SHR, including gnawing, snifﬁng, licking, and rhythmic
head movements [39]. It seemed that SHR were more sensitive to D-
AMP thanWKY. We chose the moderately low doses of 1 and 3 mg/kg
and the moderately higher dose of 5 mg/kg D-AMP to treat the rats
during the prepulse inhibition task (PPI) in order to avoid inﬂuences
of the stereotypical behaviors resulting from the higher dose of
10 mg/kg. In the PPI study, SHR showed impaired inhibition at the
higher prepulse inhibition level (85 dB) after saline injection.
Moreover, the defect of inhibitory ability in SHR under 85 dB prepulsestimulus disappeared after administration of 1 mg/kg and 3 mg/kg
amphetamine. But the inhibition ability in SHR compared toWKYwas
downregulated at the higher prepulse stimulus (85 dB) after injection
of 5 mg/kg amphetamine. In humans, disruption of PPI has been
reported in ADHD children, but the lower dose of methylphenidate
may have increased inhibition in ADHD children when compared to
the children who did not receive medicine [40]. In rodents,
amphetamine may disrupt PPI and startle reactivity in a dose-speciﬁc
manner [41,42]. In our study, there was no disruption of inhibition in
SHR after administration of 3 mg/kg amphetamine.
We used changes in the expression of the nuclear protein, c-fos, as
a substitutional measure of neural activation in order to assess SHR vs.
WKY differences in the cortical neural response to amphetamine. We
measured the protein level of c-fos in PFC to identify any functional
alterations in PFC after systemic administration of D-AMP. Our study
showed that there was increased c-fos expression in the prefrontal
cortex of SHR compared to WKY after administration of 3 mg/kg
amphetamine. Also the gene level of c-fos was higher in SHR than
WKYafter amphetamine injection. Other authors found no differences
in the basal level expression of c-fos between SHR andWKY in cortex,
striatum, and nucleus accumbens [43]. Therefore, we deduced that an
increased neuronal activity in PFC may contribute to the lower
locomotor activity and proper PPI responses in SHR after an acute
injection of 3 mg/kg D-AMP.
In clinics, psychostimulants are prescribed for at least 7 days [44].
Therefore, we tried to determine the neurobiological changes after
repeatedadministrationof amphetamineat amoderate dose (3mg/kg).
Both SHR andWKY showed obvious hyperactivity in an open-ﬁeld box
after the second injection of amphetamine and the reaction was
sustained up to the last day of drug administration. This behavioral
sensitization has been demonstrated for many amphetamine-induced
behaviors [45], including locomotion, stereotypical behavior, and
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information about how such behavioral differences mentioned above
using amphetamine can be translated into differential neural activity
in cortico-striatal neural circuits,which are the open-ﬁeld test and PPI-
regulatory circuitry [47]. A recent study of methylphenidate (Ritalin),
one of the popular prescribed drugs for ADHD children, chronically
administered to normal juvenile rats resulted in short-term effects on
the rat mPFC, striatum, hippocampus, and hypothalamus. Meanwhile,
Ritalin reduced the rats' anxiety-like behaviors [48].
As dopamine receptors play an important role in regulation of
immediate early genes (IEGs) expression, such as c-fos, we explored
the responses of dopamine-related genes in PFC after repeatedFig. 8. Relative expression of dopamine-related genes in the prefrontal cortex after
repeated amphetamine treatments using quantity real-time PCR. The ΔΔCT method
was used to determine the relative gene quantity (Fold induction=2− [ΔΔ]). (A)
Gene expression level changes, data of SHR received amphetamine vs. WKY
received amphetamine. (B) Left columns showed gene expression level changes,
data of WKY used saline compared to WKY received amphetamine. Right columns
showed gene expression level changes, data of SHR used saline compared to SHR
received amphetamine. WKY D-AMP treatment vs. saline treatment, signiﬁcant
differences are indicated by ⁎pb0.05, ⁎⁎pb0.01. SHR D-AMP treatment vs. saline
treatment, signiﬁcant differences are indicated by #pb0.05. Tyrosine hydroxylase— TH;
Dopamine transporter — DAT; Dopamine receptor 1 — DRD1; Dopamine receptor 2 —
DRD2; Dopamine receptor 3—DRD3; Dopamine receptor 4—DRD4; Dopamine receptor
5 — DRD5.
Fig. 9. Relative basal expression of SNAP-25 gene in the prefrontal cortex betweenWKY
and SHR measured using quantity real-time PCR. WKY vs. SHR, signiﬁcant differences
are indicated by ⁎pb0.05.amphetamine administrations. The results showed that dopamine 1
receptor increased after amphetamine injection in the PFC of both SHR
and WKY. Dopamine 2 and 3 receptor gene expression also increased
in WKY. A recent study provided evidence that the effects of a low
dose of D-AMP in increasing locomotor activity are mediated by D1-
receptors [49]. D1-like receptors are positively coupled to adenyl
cyclase, which activates cAMP and induces increases in the locomotor
activity. Besides, D1-like receptor agonist produces a pronounced
increase in c-fos expression in the cortical area in SHR [43]. These
results may induce the hyperactivity in SHR, and higher level of c-fos
protein expression in PFC after repeated or acute injection of D-AMP.
D2/D3 receptor stimulation after D-AMP exposure may play a
neuroprotective role in the cortex. The stimulation of D2 presynaptic
autoreceptors might exert neuroprotective effects by a negative
feedback mechanism, reducing the release of dopamine for oxidation
bymonoamineoxidase [50]. SHRdidnot showan increase of D2 andD3
receptors after repeated administrations of amphetamine, indicating
that there is a potential neuronal damage through deﬁcit of D2-like
receptors protective functions in the PFC of the SHR [51]. However, the
exact mechanism of behavioral and neurobiological alterations after
the repeated administrations of amphetamine is still unclear.
The most compelling evidence that dopaminergic mechanisms
were involved in ADHD is by pharmacological challenge in both
animals and humans. In our study, there are less dopamine-related
gene responses to D-AMP in SHR and WKY. Therefore, the question
remains whether any other central factors that regulate the process of
dopaminergic neurotransmission are involved in the origins of ADHD.
In this study, we speculated that “synaptogenesis hypotheses” might
be involved in ADHD [52].
A large number of proteins have been identiﬁed at nerve terminals
involved in the cycling of synaptic vesicles. Studies have revealed that
the SNARE (soluble N-ethylmalemide-sensitive factor attachment
protein receptors) core complex, consisting of synaptobrevin VAMP
(vesicle-associated membrane protein— a synaptic vesicle-associated
protein), syntaxin, and SNAP-25, plays essential roles in synaptic
vesicle exocytosis [53]. The SNARE complex interacts with calcium
channels that provide calcium for triggering exocytosis in the central
nervous system [54]. Disruption of this interaction alters the Ca2+-
dependence of neurotransmitter release at the neuromuscular
junctions [55]. SNAP-25 not only plays a key role in the presynaptic
775Q. Li et al. / Biochimica et Biophysica Acta 1792 (2009) 766–776regulation of synaptogenesis [52], but is also involved in the
regulation of neuronal excitability via controlling calcium responsive-
ness to depolarization [56]. Besides, SNAP-25 is expressed in axons
and nerve terminals and is essential for neurotransmitter storage and
release [57,58]. SNAP-25 is therefore a multifunctional protein that
participates in exocytotic function both at the mechanistic and
regulatory levels. Above all, we speculated that a reduced release of
dopamine in PFC might be caused by an impaired vesicular storage
and/or a reduced release of dopamine from neurons in SHR [59]. This
may explain our ﬁndings of the defects of dopamine storage and/or
release in mesocortical and mesolimbic dopamine pathways in SHR.
This ﬁnding might also be explained by the compensation of SNAP-25
for the continually increased dopamine secretion in the presynaptic
area. In further studies, it would be interesting to demonstrate the
relationship between SNAP-25 and the expression of dopamine-
related genes. Also, the relationship between the agonists and
antagonists of SNAP-25 and the dopamine system should be explored.
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